Current drug hypersensitivity challenges facing patients with cystic fibrosis
Journal of Cystic Fibrosis · 2026-07 · 25 (4) · 613-620
DOI: 10.1016/j.jcf.2026.01.010 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Cystic Fibrosis, 2026-07. Verfasst von Joshua Gardner und 5 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, United Kingdom. Electronic address: …. Hauptthemen laut MEDLINE: Cystic Fibrosis, Drug Hypersensitivity, Cystic Fibrosis Transmembrane Conductance Regulator. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Wellcome, UK Research and Innovation Medical Research Council.
Abstract (Originalsprache)
This review explores the changing landscape of drug safety in patients with cystic fibrosis (CF) prescribed Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulator therapy. While serious adverse reactions are infrequent, they can necessitate treatment withdrawal and thereby negatively impact clinical outcomes. The CFTR correctors (vanzacaftor, elexacaftor, tezacaftor, lumacaftor) and potentiators (ivacaftor, deuterated ivacaftor) target the underlying CFTR defect to improve protein function. The CF patient population encounter a high prevalence of non-immediate adverse drug reactions and T-cell mediated hypersensitivity to β-lactam antibiotics are among the most well characterised. Piperacillin has been defined as a leading drug culprit within non-immediate drug allergy in patients with CF, with a growing body of evidence alluding to the central role of T-lymphocytes. The prevalence of reactions in CF is likely due to factors including exaggerated inflammation, overactive immune states and cumulative drug exposure. While the introduction of the CFTR modulators has led to improvements in patients inflammatory and immune states, some patients have been reported to develop drug-related allergies. Uniquely, patients presenting with drug hypersensitivity have been found to later tolerate CFTR modulators, often without the need for desensitisation protocols. This phenomenon has led us to hypothesise that increased levels of inflammation and dysregulation of regulatory T-cells in CF patients could propagate adverse reactions to CFTR modulators that resolve alongside underlying infection. The introduction of CFTR modulator therapies has been highly transformative for patients with CF, therefore, adverse reactions to these compounds that lead to cessation of treatment are serious and important to understand.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, United Kingdom. Electronic address: Joshua.gardner@liverpool.ac.uk.
- Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, United Kingdom.
- Leeds Institute of Medical Research, University of Leeds, UK.
- Regional Adult Cystic Fibrosis Unit, St James's Hospital, Leeds, UK.
- Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany…
Förderung
- Wellcome Trust
- Wellcome
- UK Research and Innovation Medical Research Council
Zitieren
APA
Gardner, J., Clarke, E., Peckham, D., Whitaker, P., Roehmel, J. F., & Naisbitt, D. J. (2026). Current drug hypersensitivity challenges facing patients with cystic fibrosis. Journal of Cystic Fibrosis, 25(4), 613-620. https://doi.org/10.1016/j.jcf.2026.01.010
Vancouver
Gardner J, Clarke E, Peckham D, Whitaker P, Roehmel JF, Naisbitt DJ. Current drug hypersensitivity challenges facing patients with cystic fibrosis. Journal of Cystic Fibrosis. 2026;25(4):613-620. doi:10.1016/j.jcf.2026.01.010
BibTeX
@article{Gardner2026,
author = {Gardner, Joshua and Clarke, Elsie and Peckham, Daniel and Whitaker, Paul and Roehmel, Jobst F and Naisbitt, Dean J},
title = {Current drug hypersensitivity challenges facing patients with cystic fibrosis},
journal = {Journal of Cystic Fibrosis},
year = {2026},
volume = {25},
number = {4},
pages = {613--620},
doi = {10.1016/j.jcf.2026.01.010}
}
EUVIMED